Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

Shenton Research

Shenton Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>The HSI Sep 2026 implementation included two ADDs, and the first implementation week is complete.</li>
<li>Both ADDs rose on implementation day, unlike most historical negative-bridge ADDs.</li>
<li>The first week split. Weichai Power ended down, in line with history, and Hua Hong Grace ended up.</li>
</ul>


The HSI Sep 2026 implementation included two ADDs, and the first implementation week is complete.
Both ADDs rose on implementation day, unlike most historical negative-bridge ADDs.
The first week split. Weichai Power ended down, in line with history, and Hua Hong Grace ended up.


HSI Sep 2026 Index Rebalance: Post-Implementation Review

Hua Hong Semiconductor

HSI Sep 2026 Index Rebalance: Post-Implementation Review